Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Other Operating Expenses (2017 - 2022)

Lexaria Bioscience's Other Operating Expenses history spans 6 years, with the latest figure at $1.5 million for Q3 2022.

  • Quarterly results put Other Operating Expenses at $1.5 million for Q3 2022, changed N/A from a year ago — trailing twelve months through May 2023 was $1.5 million (changed N/A YoY), and the annual figure for FY2022 was $1.5 million, changed 0.0%.
  • Other Operating Expenses for Q3 2022 was $1.5 million at Lexaria Bioscience, roughly flat from $1.5 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.5 million in Q1 2021 to a low of -$247835.0 in Q4 2020.
  • The 5-year median for Other Operating Expenses is $769583.0 (2019), against an average of $679176.2.
  • The sharpest move saw Other Operating Expenses surged 25846.55% in 2019, then plummeted 132.2% in 2020.
  • Year by year, Other Operating Expenses stood at $549964.0 in 2018, then skyrocketed by 39.93% to $769583.0 in 2019, then plummeted by 132.2% to -$247835.0 in 2020, then surged by 714.4% to $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $1.5 million, $1.5 million, and -$247835.0 for Q3 2022, Q1 2021, and Q4 2020 respectively.